Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (MIBC)

Next Previous
X
Search
Trial Profile

A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (MIBC)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitroxoline (Primary) ; Tislelizumab (Primary)
  • Indications Bladder cancer; Carcinoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms ANTICIPATE
  • Sponsors Jiangsu Yahong Pharmaceutical Technology

    • Most Recent Events

    • 28 Aug 2024 According to an Asieris Pharmaceuticals media release, data read-out from the phase II trial is expected in September 2024.
    • 29 Jan 2024 According to an Asieris Pharmaceuticals media release, interim data from this study presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
    • 29 Jan 2024 Interim analysis data for the Phase II clinical trial published in the Asieris Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top